Michael Burry Sees The Following Stocks At Most Risk Ahead Of Tax Loss Harvesting Season
Michael Burry has detailed his Q4 portfolio adjustments, strategically navigating tax-loss harvesting season by making temporary swaps and consolidating positions. He is positioning for a potential end to the AI boom and a revival in value equities, while also investing significantly in discounted Chinese stocks like BYD. Burry is cautious about Alibaba due to its AI infrastructure spending and is holding Fiserv despite a suboptimal entry point.
Klarna Group (NYSE:KLAR) Stock Moved Up to Hold by Wall Street Zen
Wall Street Zen upgraded Klarna Group (NYSE:KLAR) from a "sell" to a "hold" rating, aligning with MarketBeat's consensus "Hold" rating and an average price target of $27.79. Despite trading near its 12-month low of $12.06, the company exceeded quarterly earnings expectations, reporting $0.01 EPS against a forecasted loss of $0.06, with revenue up 26.6% year over year. Notably, CEO Sebastian Siemiatkowski purchased nearly $10 million in shares, increasing his ownership.
KeyBanc reiterates Elanco Animal Health stock rating on strong parasiticide trends
KeyBanc has reiterated an Overweight rating and a $30.00 price target for Elanco Animal Health, based on strong parasiticide trends observed in a recent survey of veterinary clinics. The survey indicated that broad-spectrum parasiticides are performing well, with 64% of clinics prescribing more than the previous year, and Elanco's Quattro and Zenrelia products showing strong, efficacy-driven adoption. This positive outlook for Elanco contrasts with some challenges faced by Zoetis, whose shares are trading near a 52-week low despite appearing undervalued by InvestingPro analysis.
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
The article analyzes the Q2 earnings performance of pharmaceuticals stocks, highlighting Jazz Pharmaceuticals (NASDAQ:JAZZ) as a strong performer with revenues up 15.5% year-on-year, though its stock price dipped post-earnings. Bristol-Myers Squibb (NYSE:BMY) also had an impressive quarter, while Zoetis (NYSE:ZTS) was the weakest performer with flat revenues and missed expectations. The pharmaceuticals sector as a whole reported strong Q2 results, with revenues beating estimates by 5.5%.
KeyBanc reiterates Elanco Animal Health stock rating on strong parasiticide trends
KeyBanc has reiterated an Overweight rating and a $30.00 price target for Elanco Animal Health (NYSE:ELAN) due to strong parasiticide trends. A recent survey of U.S. veterinary clinics indicated robust demand for broad-spectrum parasiticides, with 64% prescribing more than last year. The analyst also noted competitive pressures on Zoetis’s Simparica Trio are mainly economic, supporting Zoetis's gross-to-net strategy, while Elanco's products like Quattro and Zenrelia are gaining traction.
What Is Drawing Attention To Axogen (AXGN)?
Axogen (AXGN) has garnered attention due to recent share price movements, showing a decline over the past month and three months but significant gains over the last year. Despite the recent pullback, which has brought its price to approximately 11% below an estimated intrinsic value and 25% below the average analyst target, the company's valuation narrative suggests it is 19% undervalued at $53.22. However, the article also notes potential risks due to Axogen's reliance on its Avance Nerve Graft and a high P/S ratio compared to industry peers.
ABIVAX Société Anonyme (ENXTPA:ABVX) Following New Leadership Hires And Wider Losses Looks Undervalued
ABIVAX Société Anonyme (ENXTPA:ABVX) is considered undervalued despite recent leadership changes, wider first-half losses, and increased cash usage. The company's lead drug, obefazimod, has shown strong Phase 3 results for ulcerative colitis, and the company has secured sufficient funding to avoid immediate capital raises. While the stock trades at a steep discount to analyst targets, its P/B ratio is high compared to the broader French biotech sector, indicating split sentiment among investors.
Absci Stock In Focus As Phase 2 Trial Plan Takes Shape
Absci has detailed the plan for its global Phase 2 STORYLINE trial of ABS-201 for endometriosis, which will be a double-blind, randomized, placebo-controlled study targeting about 150 patients across at least 10 countries. This trial aims to test a differentiated, nonhormonal approach using Absci's generative AI engineered anti-PRLR antibody. The company's investment narrative heavily relies on the success of ABS-201, with minimal current revenue and ongoing losses, projecting significant revenue and earnings growth by 2029 if the trial proves successful.
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Consensus Price Target of $23.57 According to Brokerages
Eleven ratings firms have given Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) a "Reduce" recommendation, with an average 12-month price target of $23.57. Despite this cautious sentiment, the company reported stronger-than-expected quarterly results, with adjusted earnings of $0.66 per share and revenue of $5.55 billion. Institutional ownership of FMS stock has increased, although collective institutional holdings remain at 8.37%.
Veeco Instruments Inc. (NASDAQ:VECO) Stock Now Rated "Hold" by Wall Street Analysts
Veeco Instruments (NASDAQ:VECO) has received a consensus "Hold" rating from Wall Street analysts, with an average 12-month price target of $61.33, significantly above its current trading price of $45.45. The company recently surpassed quarterly earnings expectations, reporting $0.33 EPS and $193.48 million in revenue. Despite strong institutional ownership, recent insider sales by the CEO and CFO have been noted.
GAMCO Natural Resources, Gold & Income Trust Q2 2026 Commentary (GNT)
The GAMCO Natural Resources, Gold & Income Trust (GNT) Q2 2026 commentary highlights significant market declines in gold bullion, crude oil, and agribusiness, with gold down 14.1% and crude oil down 31.4%. GNT responded by increasing its cash position to 24% and maintaining diversified sector allocations across gold/base metals, agriculture, and energy to manage volatility. The fund also increased its monthly distribution to $0.06 and continued its covered call strategy to generate income despite market turmoil.
Why Did Agilent Technologies (A) Shares Climb After Its Latest Update?
Agilent Technologies (A) recently saw its shares climb after expanding its clinical lab footprint with new CE-IVD-labeled TapeStationDx instruments and software for DNA and RNA quality control in regulated next-generation sequencing workflows. The company has experienced significant share price returns, indicating building momentum. Despite being considered 4% undervalued by a fair value narrative, the article notes potential risks from elevated tariff costs or tightened research funding.
Andra AP fonden Buys 62,718 Shares of Ameriprise Financial, Inc. $AMP
Andra AP fonden significantly increased its stake in Ameriprise Financial, Inc. (NYSE:AMP) during the second quarter, purchasing 62,718 additional shares and bringing its total holdings to 70,518 shares valued at approximately $32.4 million. Despite the firm exceeding quarterly earnings and revenue expectations, Ameriprise shares recently fell 4.5% to $511.45. Analyst sentiment remains generally positive, with the stock holding a "Moderate Buy" consensus rating and an average price target of $555.33.
Grifols (NASDAQ:GRFS) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded Grifols (NASDAQ:GRFS) from a "hold" to a "buy" rating, despite a broader analyst consensus of "Reduce." The company's shares opened at $7.31, close to its 52-week low, with a market capitalization of $4.98 billion. Several institutional investors, including Tidal Investments and Hennion & Walsh Asset Management, have recently increased their holdings in Grifols.
Is IDEXX Laboratories Stock Underperforming the Dow?
IDEXX Laboratories (IDXX) stock has significantly underperformed the Dow Jones Industrial Average over the past year and in 2026, with shares down 23.9% year-to-date and 21.4% over 52 weeks, compared to the Dow's positive returns. Despite this, the company showed improving momentum in Q2, with strong revenue and EPS growth, and analysts maintain a "Moderate Buy" rating with a substantial price target premium. The underperformance is attributed to investor concerns about slower veterinary clinic traffic, though recent results suggest a recovery.
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market
Cosmos Health Inc. has launched C-ScrubVet, a veterinary antimicrobial cleanser, in the UK, marking its entry into the global animal health market. This product, formulated for various animals and certified under European standards, leverages an existing C-Scrub formulation and the company's in-house manufacturing capabilities. The launch is part of a phased, multi-channel rollout, with plans to expand into other European markets and contribute to the company's 2029 financial guidance of $200.6 million in revenue.
DAQO New Energy Corp. (NYSE:DQ) Given Average Recommendation of "Reduce" by Brokerages
DAQO New Energy Corp. (NYSE:DQ) has received a consensus "Reduce" rating from seven brokerages, with an average 12-month price target of $19.36. The company's shares opened at $12.49, near its one-year low, and it reported a quarterly loss of $1.20 per share, missing analyst expectations despite exceeding revenue estimates. Several analysts have recently lowered their ratings or price targets for the stock.
Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock
Gilead Sciences CEO Daniel Patrick O'Day sold 15,000 shares of company stock for $2.23 million on September 1st, under a pre-arranged Rule 10b5-1 plan. This sale reduced his position by 2.53%, leaving him with 577,133 shares. The transaction follows previous sales in August and July and comes as Gilead reported strong Q2 revenue of $7.80 billion, exceeding analyst estimates, and announced a quarterly dividend of $0.82 per share.
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Zoetis Inc. (NYSE: ZTS) announced that its CEO, Kristin Peck, and CFO/COO, Jay Saccaro, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, at 1:50 p.m. ET. A live audio webcast will be available on the company's investor relations website, with a replay accessible after the event. Zoetis, a leading animal health company, aims to advance animal care globally.
Zoetis Inc. Class A (ZTS) Shareholding Pattern – Promoters, FIIs & DIIs
This article provides a detailed shareholding pattern for Zoetis Inc. Class A (ZTS), listing institutional investors with holdings greater than 1% across various quarters. It also includes recent insider trade data, specifically sell transactions by Ro Khanna and Gilbert Ray Cisneros, Jr., and a buy transaction by Gilbert Ray Cisneros, Jr. The article further offers key financial metrics for ZTS, such as market cap, revenue, P/E ratio, P/B ratio, and dividend yield, as of August 28, 2026.
JATT mastermind launches latest biotech-focused SPAC in $60M IPO
Biotech entrepreneur Someit Sidhu has launched his latest Special Purpose Acquisition Company (SPAC), JATT III Acquisition, with a $60 million IPO on the Nasdaq. This marks Sidhu's third SPAC endeavor, aimed at taking a privately listed biotech or life sciences company public through a reverse merger, focusing on data-driven approaches. The launch follows his previous successful SPACs, JATT Acquisition and JATT II, despite a general decline in SPAC popularity among biotechs.
BlackRock Inc. Makes New Investment in Sunstone Hotel Investors, Inc. $SHO
BlackRock Inc. has acquired 35.1 million shares of Sunstone Hotel Investors, Inc. (NYSE:SHO) during the second quarter, representing an 18.85% stake valued at approximately $402.1 million. Institutional investors now own 99.37% of the REIT. Sunstone Hotel Investors exceeded quarterly earnings and revenue estimates and declared a quarterly dividend of $0.09 per share.
ZTS Maintained by TD Cowen -- Price Target Lowered to $94.00
TD Cowen has maintained a Buy rating on Zoetis (ZTS) but lowered its price target from $104.00 to $94.00, reflecting a cautious outlook amidst changing market conditions. Despite this adjustment, GuruFocus indicates that ZTS is significantly undervalued with a GF Value™ of $180.56 against a current price of $76.54, and boasts a solid GF Score™ of 66/100, particularly strong in profitability. This suggests a potential long-term investment opportunity in the animal health sector.
TD Cowen cuts Zoetis stock price target on clinic visit declines
TD Cowen has reduced its price target for Zoetis (NYSE: ZTS) to $94 from $104, while maintaining a Buy rating, due to declining clinic visits for U.S. canine dermatology and parasiticides, as well as price pressure and competition. The firm revised its near-term estimates for 2026 and 2027, projecting flat revenue for 2026 and 1% EPS growth, although it expects a 4% revenue growth and 8% EPS compound annual growth rate from 2025 through 2032. This comes amidst recent mixed second-quarter results and downward revisions in full-year guidance from Zoetis, leading other firms like William Blair and Stifel to also adjust their ratings and price targets.
Jeffrey Graves Sells 115,500 Shares of 3D Systems (NYSE:DDD) Stock
Jeffrey Graves, CEO of 3D Systems, sold 115,500 shares of the company's stock for $376,530, reducing his direct ownership by 8.08%. Despite recent positive earnings surprises and analyst forecast improvements suggesting narrowing losses through 2028, the company is expected to remain unprofitable. The stock currently has an average "Hold" rating from analysts with a price target of $5.50.
Why Did Neogen (NEOG) Lose A Board Member And What Changes Now?
Neogen Corporation (NEOG) announced the resignation of board member Thierry Bernard. This change adjusts the composition of Neogen's board, which is crucial for overseeing the company's focus on food and animal safety, integration challenges, and margin improvements. While Bernard's departure slightly weakens governance, the company's narrative is also driven by regulatory tailwinds and operational fixes, raising questions about the refreshed board's ability to match peers in specialized experience.
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
The article reviews the Q2 earnings season for the pharmaceuticals industry, highlighting Ocular Therapeutix (OCUL) as a strong performer with flat year-on-year revenue that still beat analyst expectations. It also discusses Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) for strong Q2 results, while noting Zoetis (ZTS) had a weaker quarter despite a slight stock increase. The industry as a whole saw revenues beat estimates by 5.4%, with stock prices up 5% on average.
FY2026 EPS Estimate for Bausch Health Cos Raised by Analyst
Zacks Research has increased its FY2026 EPS estimate for Bausch Health Cos (NYSE:BHC) to $4.24 from $3.93, while maintaining a "Strong Sell" rating. This adjustment aligns with the current consensus forecast. The company recently exceeded earnings expectations, reporting an EPS of $1.26 against a consensus of $0.96 and revenue of $2.83 billion against an expected $2.59 billion.
GE HealthCare names new CFO
GE HealthCare has appointed William Grogan as its new CFO, filling the vacancy left by Jay Saccaro. Grogan, formerly CFO at Xylem, is set to join GE HealthCare on September 14, 2026. Analysts from Stifel and RBC Capital Markets have welcomed the appointment, citing Grogan's strong track record in meeting earnings expectations, expanding margins, and simplifying operating systems, despite his lack of specific medtech experience.
160,631 Shares in Elanco Animal Health Incorporated $ELAN Purchased by First National Bank of Omaha
First National Bank of Omaha recently acquired 160,631 shares of Elanco Animal Health (NYSE:ELAN) valued at approximately $3.97 million during the second quarter. This purchase contributes to institutional investors collectively owning 97.48% of ELAN's outstanding stock. Elanco exceeded quarterly earnings and revenue expectations, and analysts maintain a "Moderate Buy" rating with an average price target of $29.09.
Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to Commercialization
Amylyx Pharmaceuticals (AMLX) stock surged to a new three-year high following strong Phase 3 clinical trial results for its drug candidate Avexitide, a treatment for post-bariatric hypoglycemia (PBH). The drug successfully reduced low-blood-sugar episodes by 55% and met all secondary endpoints, leading to increased price targets from several investment firms. Amylyx plans to submit a new drug application to the FDA by year-end, aiming for commercialization in 2027, addressing a significant unmet medical need as there are currently no FDA-approved therapies for PBH.
Deutsche Bank AG Purchases 319,709 Shares of Zoetis Inc. $ZTS
Deutsche Bank AG increased its stake in Zoetis Inc. by 5.8% in the second quarter, acquiring an additional 319,709 shares, bringing its total holdings to 5.85 million shares valued at approximately $420.5 million. Other institutional investors also adjusted their positions, with collective institutional ownership reaching 92.8%. Despite a consensus "Hold" rating from analysts and a target price of $109.62, several firms have recently lowered their price targets for Zoetis.
ZTS Shareholders Have Opportunity to Lead Zoetis Inc. Class Actio
A class action lawsuit has been filed against Zoetis Inc. (NYSE:ZTS) and its officers, alleging that they made false and misleading statements regarding the growth and market share of key Companion Animal products. Shareholders who purchased Zoetis securities between January 14, 2025, and May 6, 2026, are encouraged to join the lawsuit, with a deadline of July 27, 2026, to request appointment as lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is representing investors on a contingency fee basis.
Fifth Third Bancorp Decreases Stake in Zoetis Inc. $ZTS
Fifth Third Bancorp reduced its stake in Zoetis Inc. by 20.6% in the second quarter, selling 29,167 shares and holding 112,370 shares valued at $8.1 million. Despite a recent earnings beat and a declared dividend, Zoetis shares have seen a significant drop from their 52-week high, prompting analysts to issue a consensus "Hold" rating with an average price target of $109.62. Institutional investors collectively own 92.8% of the company's stock.
Principal Financial Group Inc. Trims Stake in Zoetis Inc. $ZTS
Principal Financial Group Inc. reduced its stake in Zoetis Inc. by 4.4% in the second quarter, selling 24,472 shares but still holding 527,859 shares valued at $37.9 million. Other institutional investors, such as J. Stern & Co. LLP and Vanguard Group Inc., significantly increased their holdings in Zoetis. The stock currently holds a consensus "Hold" rating from analysts with a target price of $109.62, and the company recently reported quarterly earnings that slightly beat estimates despite a revenue decline.
Bank of America Corp DE Increases Position in V2X, Inc. $VVX
Bank of America Corp DE significantly increased its stake in V2X, Inc. by 26.5% during the first quarter, now holding 517,369 shares valued at $35.4 million. Despite institutional investors owning a large portion of the company, analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $86.90. V2X recently surpassed earnings and revenue expectations, reporting $1.64 EPS and $1.26 billion in revenue.
Brandes Investment Partners, LP's Top Q2 2026 Move: CNH Industrial NV at a 1.51% Portfolio Impact
Brandes Investment Partners, LP made significant portfolio adjustments in Q2 2026, prominently increasing its stake in CNH Industrial NV by 704.31%, leading to a 1.51% portfolio impact. The firm also added 18 new stocks, with Zoetis Inc, Capital One Financial Corp, and Vanguard FTSE Developed Markets ETF being the largest additions, and completely exited 11 holdings including Nutrien Ltd. These changes reflect Brandes' value-oriented strategy, focusing on undervalued industrial and consumer names while maintaining a diversified portfolio across 11 industries.
Coeur Mining Stock Is Priced On Its Margin
Coeur Mining (CDE) stock has returned 56% over the last year but trades below its 52-week high, presenting a valuation that appears cheaper than the S&P 500 on earnings and more expensive on sales. This dual valuation is attributed to the company's high operating margin. The miner's future performance hinges on its newly acquired Canadian mines reaching production targets and stable metal prices, with historical data showing its stock's sensitivity to market downturns despite a strong cash balance.
Mirae Asset Global Investments Co. Ltd. Acquires 3,726 Shares of Humana Inc. $HUM
Mirae Asset Global Investments Co. Ltd. increased its stake in Humana Inc. by 14.5% during the second quarter, acquiring an additional 3,726 shares and bringing its total holdings to 29,374 shares valued at approximately $11.7 million. Institutional investors now own 92.38% of Humana's shares. Humana recently exceeded quarterly earnings expectations with an adjusted EPS of $7.61 and revenue of $40.89 billion, although its stock trades below its 52-week high.
Lululemon leads large-caps as a potential acquisition target with 79.8% fair value upside
Lululemon Athletica is identified as a prime acquisition target among large-cap U.S. stocks due to its significant 79.8% fair value upside, strong financials, and premium brand status despite a recent stock decline. The article highlights its low price-to-earnings ratio and healthy balance sheet as key attractors for potential buyers. Other companies like Adobe, Zoetis, and Intuit are also mentioned as potential targets, though with caveats regarding their market cap or debt levels.
Zacks Industry Outlook Highlights Aflac, Globe Life, Trupanion and Employers Holdings
The Zacks Accident and Health Insurance industry is expected to benefit from increased underwriting exposure, with Aflac, Globe Life, Trupanion, and Employers Holdings poised for growth due to rising demand for group insurance. However, the industry faces challenges from persistent medical inflation and pricing pressures, despite advancements in technology like AI and improved claims frequency. The industry currently holds a Zacks Industry Rank #214, indicating bleak near-term prospects despite individual company advancements.
Why Did This Digital Asset Stock Soar More Than 49% Today?
Forum Markets Inc. (FRMM) shares surged over 53% after the company announced it would restart its share repurchase program and form a special committee for strategic review. The board believes repurchases at current price levels reflect the company's intrinsic value. The special committee will explore options like mergers, acquisitions, asset sales, and new partnerships to maximize shareholder value.
Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating
Barclays has updated its price target for IDEXX Laboratories (IDXX) to $710, down from the previous $800, while maintaining an "Overweight" rating on the stock. This adjustment reflects a revised valuation perspective for the veterinary diagnostics company. The news comes amid other analyst updates and recent financial reporting from IDEXX Laboratories.
AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook
AbCellera Biologics (ABCL) surged 44% to a three-year high following positive clinical trial results for its hot flash treatment, ABCL635. The drug significantly reduced hot flashes in postmenopausal women, outperforming a placebo, and analysts are bullish on its potential in a large addressable market. Despite a slight decrease in the number of hedge funds holding positions, their aggregate holdings in ABCL increased by 29% in the first quarter, indicating growing investor confidence.
Insider Buying: Elanco Animal Health (NYSE:ELAN) Director Buys 10,000 Shares of Stock
Elanco Animal Health (NYSE:ELAN) Director Paul Herendeen recently purchased 10,000 shares of the company's stock for $236,800, increasing his total ownership to 111,687 shares. This insider buying follows Elanco's strong quarterly earnings report, where the company beat estimates with $0.34 EPS and saw revenue increase by 10.2% year-over-year to $1.37 billion. Analysts currently hold a "Moderate Buy" consensus rating for ELAN, with an average price target of $29.09.
Insider Buying: Elanco Animal Health (NYSE:ELAN) CFO Buys $96,936.00 in Stock
Elanco Animal Health's CFO, Robert Vanhimbergen, purchased 4,200 shares of the company's stock for $96,936, increasing his holdings by 3.15%. This insider buying follows Elanco's strong quarterly results, which exceeded EPS and revenue expectations. Analysts maintain a "Moderate Buy" rating for ELAN with a consensus price target of $29.09.
Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash
Theravance Biopharma reported its Q2 2026 financial results, including $20.7 million in revenue from its Viatris collaboration and a GAAP net loss of $5.9 million, with $387.7 million in cash and marketable securities. The company highlighted strong YUPELRI performance, a pending acquisition by Zymeworks, and significant cost reductions from organizational restructuring. They also expressed confidence in achieving a $100 million milestone payment from Royalty Pharma related to TRELEGY royalties.
Bank of America Corp DE Has $80.36 Million Stake in Elanco Animal Health Incorporated $ELAN
Bank of America Corp DE significantly increased its stake in Elanco Animal Health Incorporated by 38% in Q1, bringing its total holding to $80.36 million. This comes as Elanco reported strong quarterly earnings, beating analyst expectations, and issued positive full-year EPS guidance. Analysts maintain a "Moderate Buy" rating, and company insiders have also recently purchased shares, indicating confidence in the stock.
Zoetis (ZTS) Stock Sinks After Guidance Cut Deepens Profit Concerns
Zoetis (ZTS) stock fell almost 6% after the company cut its full-year guidance, now expecting adjusted diluted earnings per share between US$6.15 and US$6.25 and a mid to high single-digit decline in organic adjusted net income. This guidance cut was largely driven by a decline in U.S. companion animal revenue, particularly in dermatology and OA pain treatments, despite growth in diagnostics and livestock segments. The article discusses whether Zoetis is now a bargain or if the lowered guidance confirms bearish concerns about competitive pressure and over-reliance on the U.S. companion animal market.
Elanco Animal Health Q2 Earnings Call Highlights
Elanco Animal Health reported strong second-quarter 2026 results, exceeding prior guidance with revenue up 10% to $1.368 billion, driven by new pet-health products like Zenrelia and Credelio Quattro, and growth in U.S. farm animal operations. The company raised its full-year organic constant-currency revenue growth outlook to 6% to 7% and improved its net leverage target. Innovation in both pet and farm animal segments, alongside productivity initiatives, are key drivers for Elanco's sustained growth.
